Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Conditions
Ulcerative Colitis (UC) · Crohn's Disease (CD) · Indeterminate Colitis · Inflammatory Bowel Disease (IBD)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale University School of Medicine, New Haven, Connecticut, United States
Contact: Principal Investigator (Jill Gaidos, MD)University of Iowa, Iowa City, Iowa, United States
Contact: Principal Investigator (Steven Polyak, MD)Mercy Medical Center, Baltimore, Maryland, United States
Contact: Principal Investigator (Ray Cross, MD)Brigham and Women's Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Jessica Allegretti, MD)New York University, New York, New York, United States
Contact: Study coordinator (Nathasha Melukkaran) · Nathasha.melukkaran@nyulangone.org · 646-754-3417Contact: Principal Investigator (David Hudesman, MD)University of North Carolina, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Hans Herfarth, MD, PhD)Atrium Health Center for Gastroenterology and Surgery, Charlotte, North Carolina, United States
Contact: Study coordinator (Jessica Kearney-Bryan) · Jessica.kearney-bryan@advocatehealth.org · 704-355-0244Contact: Principal Investigator (Maithili Chitnavis, MD)Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
Contact: Principal Investigator (Richard Bloomfeld, MD)University of Cincinnati, Cincinnati, Ohio, United States
Contact: Principal Investigator (Loren Brook, MD)
Study leads
Hans Herfarth, MD, PhD
Principal Investigator
University of North Carolina